• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Fight for swine flu vaccine could get ugly

St Michael

Well-known member
Fight for swine flu vaccine could get ugly
The Associated Press
By MARIA CHENG
7/16/09

LONDON ? An ugly scramble is brewing over the swine flu vaccine ? and when it becomes available, Britain, the United States and other nations could find that the contracts they signed with pharmaceutical companies are easily broken.

Experts warn that during a global epidemic, which the world is in now, governments may be under tremendous pressure to protect their own citizens first before allowing companies to ship doses of vaccine out of the country.

That does not bode well for many countries, including the United States, which makes only 20 percent of the flu vaccines it uses, or Britain, where all of its flu vaccines are produced abroad.

"This isn't rocket science," said Michael Osterholm, director of the Center for Infectious Diseases Research and Policy at the University of Minnesota. "If there is severe disease, countries will want to hang onto the vaccine for their own citizens."

Experts say politicians would not be able to withstand the pressure.

"The consequences of shipping vaccine to another country when your own people don't have it would be devastating," added David Fedson, a retired vaccine industry executive.

About 70 percent of the world's flu vaccines are made in Europe, and only a handful of countries are self-sufficient in vaccines. The U.S. has limited flu vaccine facilities, and because factories can't be built overnight, there is no quick fix to boost vaccine supplies.

Last week, the World Health Organization reported nearly 95,000 cases of swine flu including 429 deaths worldwide. If swine flu turns deadlier in the winter, the main flu season in the Northern Hemisphere, countries will likely be clamoring for any available vaccines.

"Pandemic vaccine will be a valuable and scarce resource, like oil or food during a famine," said David Fidler, a professor of law at Indiana University who has consulted for WHO. "We've seen how countries behave in those situations, and it's not encouraging."

Britain claims it will start vaccinating people in August, Italy says it will begin by the end of the year, and many other countries have similar strategies. Those mass vaccination plans could be derailed by problems making the vaccine and by other countries' refusal to ship it abroad.

If the virus remains mild, this could all be moot. Experts estimate swine flu to be about as dangerous as seasonal flu, and there usually isn't a high demand for those vaccines. Still, regular flu kills up to 500,000 people a year.

In past pandemics, or global epidemics, vaccines were never exported before the country that produced them got enough for its own population first.

Unlike the last two pandemics in 1957 and 1968, however, many more countries this time around have struck deals with companies which they say guarantees them first access to vaccine. Yet in a global health emergency, those contracts may ultimately be meaningless.

Countries with flu vaccine plants might decide to seize all vaccines and ban their export, thus breaking the pharmaceutical contracts promising other countries vaccine supplies. These private contracts are not binding international law between two countries, according to Fidler.

He said most vaccine contracts include a clause allowing them to be broken under extraordinary circumstances, such as a health emergency. That would leave the countries who had brokered such deals not only without vaccine, but without legal recourse.

"There's nothing in international law that helps you resolve this, it's just a political nightmare happening in the midst of an epidemiological nightmare," Fidler said.

Britain has ordered 60 million doses, enough to cover its entire population. But those doses are being manufactured by GlaxoSmithKline PLC and Baxter International Inc., whose production plants are in Germany, Austria and the Czech Republic. Neither Britain's department of health or the vaccine manufacturers would comment on delivery plans.

Osterholm said about 80 percent of the United States' pandemic vaccine supply will be coming from abroad and he is very concerned about when it might arrive. Timing could be everything to avoid a vaccine spat.

"It's easy to move vaccine around if the disease is relatively mild. But if it is more severe, countries may not be willing to let it go," he said.

So far, swine flu remains a relatively mild disease, and most people don't need medical treatment to get better. But experts fear the virus could mutate into a more dangerous form. And during the flu season, when the virus spreads more easily, more people will probably fall sick and die.

Public health officials are aware that so-called "vaccine wars" might break out if the swine flu outbreak worsens, but are loathe to even discuss the topic.

The European Centre for Disease Prevention and Control, an agency of the European Union, said it had no mandate to advise countries in such circumstances. WHO said it was not aware of any countries planning to block the shipment of vaccines and said they would work to ensure all countries get enough doses to protect their health workers.

Questions also remain about when a swine flu vaccine will even be available, as WHO reported this week that a fully licensed vaccine might not be ready until the end of the year.

With little or no safety data about a swine flu vaccine, governments that are planning to roll out mass campaigns are taking a gamble, since any rare side effects won't show up until millions of people start getting the shots.

Experts say government promises about when vaccines will arrive should be taken with a huge grain of salt.

"Many pieces of the puzzle are missing," Osterholm said. "Anyone who pretends to have a well-defined schedule of vaccine delivery is obviously very poorly informed."
 
Re: Fight for swine flu vaccine could get ugly

Swine flu shots to boost Baxter
Company reports 2nd-quarter profit increased by 13%, 2009 forecast raised
By Bruce Japsen

Tribune reporter

July 17, 2009

International demand for a swine flu vaccine is developing into a boon for Baxter International Inc.

On a day the Deerfield-based medical-product giant reported a 13 percent boost in second-quarter profit, Chairman and Chief Executive Robert Parkinson said the company's plant in the Czech Republic was running at capacity as it fills orders for 80 million dosages from five countries.

Baxter has all the work it can handle and expects production of vaccines to combat the H1NI swine flu to continue indefinitely, particularly as strains mutate, Parkinson said.

"There will be demand for whatever we will be able to produce," Parkinson told Wall Street analysts on an earnings conference call Thursday morning.

Baxter said it would begin shipping dosages of a swine flu vaccine worldwide by the end of July. Baxter could reap $30 million to $40 million in revenue from H1N1 contracts.

The quarterly revenue "does not seem to reflect any incremental swine flu vaccine sales, potentially implying that we could see some vaccine upside in the second half of the year," said Rick Wise, a Leerink Swann & Co. analyst in New York, in a note to clients.

Parkinson raised Baxter's 2009 adjusted earnings forecast to $3.76 to $3.80 per share, up from $3.72 to $3.78. The company plowed $443 million, an 8 percent increase, into new products, including its Gammagard drug for immune disorders and the swine flu vaccine.

Baxter's vaccine orders do not include the U.S., which announced this week that it was working with other manufacturers that are developing seasonal flu products and have more capacity. Baxter has said it continues to talk with U.S. health officials.

Baxter has a newer, cell-based manufacturing technology that does not require processing vaccines with chicken eggs, which can cut production times by several weeks. Because the technology is new, Baxter has not been approved to sell a seasonal vaccine in the U.S. and instead has generated sales from countries looking to stockpile vaccines to combat pandemic threats.

"While this is a significant opportunity for Baxter, it is premature to get ahead of ourselves for the next five months of the year," Parkinson said.

Wall Street responded positively to the earnings report, which beat analysts' estimates. Baxter stock ended Thursday up 3.1 percent, or $1.65 a share, at $54.74.

Baxter, which also makes blood therapies and drug-delivery devices, reported net income of $587 million, or 96 cents a share, compared with $544 million, or 85 cents in the year-ago period. Sales declined 2 percent, to $3.12 billion, as a result of the impact of foreign exchange.

U.S sales rose 7 percent, to $1.33 billion, while international sales fell 8 percent, to $1.8 billion.

www.chicagotribune.com/business/chi-fri-baxter-swine-flu-0717-jul17,0,3826525.story
 
Re: Fight for swine flu vaccine could get ugly

http://www.fiercepharma.com/story/can-vaccine-makers-deliver-flu-shot-deals/2009-07-17

Can vaccine makers deliver on flu shot deals?
July 17, 2009 ? 10:10am ET | By Tracy Staton

This week has been big on H1N1 vaccine contracts. U.K., France and Germany all announced that they'd secured millions of doses for their people. But that's not the full story. It's true that they've inked deals with drugmakers. But those deals come with a couple of assumptions: One, the vaccines will be available on schedule. Two, that they can be delivered.

And there are problems with both. Already the WHO has announced that vaccine makers are having trouble cultivating antigen from the available H1N1 strains, getting only about one-quarter the usual yield with seasonal flu. Now, two vaccine makers are warning of possible shortfalls because of that yield problem. Novartis says its yield is 30 percent to 50 percent of normal; Baxter didn't put a number to it, but said optimizing yields "is proving a challenge."

As you know, vaccine manufacturing depends on the antigen. And that means millions of vaccine doses could arrive later than those government customers expect. Already Baxter has warned the U.K. that it's sending over smaller quantities than expected at the end of next month, and it's saying that it can't accept any more orders. WHO is fiddling with the virus in hopes of getting a better-yielding version to vaccine makers, and the manufacturers are tweaking their processes in an attempt to boost yield.

Meanwhile, some experts are raising questions about getting the shots to customers once they're made. This won't be a problem for at least one of France's contracts; Sanofi-Aventis will be making its 28 million doses (plus an optional 28 million more) right there in the country. But it could be a major snag for countries whose orders have to be shipped across national borders.

Just think: A manufacturing plant is churning out millions of doses for foreign customers, but its home country doesn't have enough shots--or has none at all. That country might seize the vaccine shipments. That country could cut off shipments till it gets what it considers its share. Obviously the risk is greatest if the virus evolves to greater virulence.

Now the inevitable question is, which countries are most at risk of seeing their vaccine contracts go unfulfilled? Which leads us to follow-up question No. 2: Where is flu vaccine made? Eleven countries account for 90 percent of it, and they include the U.S., Australia, Japan, and other "high-income" countries.
 
Re: Fight for swine flu vaccine could get ugly

The one slight advantage for the UK, is that GSK is a British company, so it is less likely to hand over vaccines or co-operate with a foreign government. However, if you're ordering from a company like Baxter which is American and based in America, you haven't got a lot of hope if the US decide to divert the vaccines.
 
Re: Fight for swine flu vaccine could get ugly

#1:
"About 70 percent of the world's flu vaccines are made in Europe, and only a handful of countries are self-sufficient in vaccines. The U.S. has limited flu vaccine facilities, and because factories can't be built overnight, there is no quick fix to boost vaccine supplies."



It's time worldwide to involve the mil facilities into civilian vacc production also.
 
Re: Fight for swine flu vaccine could get ugly

Let's suppose somehow various countries manage to get some supplies of the precious vaccine, by negotiation, by trade war, or by war...

Governments then will determine who will obtain the shots.

WHO said health care workers first, governments decide who else.

What say the citizens?

Here's below one example where a group of citizens is starting to think on how to get as high up as possible on the priority list of the "Golden Shots". Of course (so it is said), get vaccination to the priority people first, then... think of us Olympic Games sports people? Food for thought...

2010 Games eyes vaccinations against H1N1

Wednesday, July 15, 2009; 7:37 PM

VANCOUVER, British Columbia (Reuters) - Organizers of next year's Winter Olympics in Vancouver are hoping to get thousands of volunteers and staff vaccinated against the H1N1 flu virus, a medical official said on Wednesday.

Organizers were already stockpiling antivirals and vaccine for next year's expected seasonal flu in Canada and are now talking with Canadian and international health authorities about how to respond to the global swine flu pandemic.

"We'll be doing a campaign trying to encourage all of our volunteers as well as our staff ... to get as many as possible vaccinated," said Dr. Jack Taunton, chief medical officer of the Vancouver Organizing Committee (VANOC).

The 2010 Games to be held in the west coast city in February will draw athletes, officials and visitors from around the world.

They will also involve 25,000 volunteers and 5,000 VANOC staff. Vaccinations cannot be mandated in Canada, so Taunton said that, based on past medical experience, it is unlikely all of the volunteers and staff would agree to do it.

Vaccination of athletes is the responsibility of each country's national Olympic committees but Taunton said VANOC will be advising those committees about which flu viruses they should be protecting against.

VANOC highlighted the concern about the potential impact of the H1N1 flu on the Games with the announcement on Wednesday that its latest sponsor was ALDA Pharmaceuticals Corp, which produces hand sanitizers.

Medical officials say hand washing is a critical component in efforts to stop the flu's spread.

"This is a product for the times we are in," VANOC chief executive John Furlong told reporters.

The World Health Organization this week recommended healthcare workers should get priority access to H1N1 vaccinations to ensure health systems keep functioning as the swine flu pandemic spreads.

WHO also recommended priority for pregnant women, children and people with underlying diseases.

"We know there are other priorities and that we have to fit within that," Taunton said. "We're not going to be stepping up to the front of the line."

Taunton said VANOC also recognized that development of a potential vaccine for the H1N1 flu has gone slower than some health officials had hoped.

"If it was produced at the same rate as seasonal flu (vaccine), we would be fine," he said.

(Editing by John O'Callaghan)
 
Re: Fight for swine flu vaccine could get ugly

From Times Online
July 17, 2009

Doubts surface over UK swine flu vaccine supply

Contracts for swine flu vaccine held by countries such as Britain with pharmaceutical companies abroad could be broken easily if governments decide to impose export bans as the pandemic worsens.

Experts warn that the pressure on governments to prevent vaccine supplies from being sent abroad while their own populations are suffering could be very high if death rates spiral ? and make contracts difficult to enforce.

Professor Peter Dunhill, of the Department of Biochemical Engineering, University College London, told The Times that ?nationalising? policies would be inevitable at the peak of a severe pandemic, with politicians unable to resist public demand to stop shipments.

?If you look at the situation, the amount of vaccine being produced globally is very small,? Prof Dunhill said.

?The issue should not come up unless things get really bad, because I think people will show a degree of caution about getting vaccinated. But if the backstops fall away and this virus gets more troublesome and resistant to anti-virals, then the issue becomes much sharper.

?Pharmaceutical companies will not want to constrain availability to the most powerful buyers in the drugs markets. But they may find that governments just dictate.?

Prof Dunhill said it would become ?politically impossible? for leaders not to block shipments of vaccine from leaving the country, just as the United States did in 1976 when it reneged on a vaccine agreement with Canada. However such problems are unlikely to rise if the pandemic remains mild.

His comments came as the US pharmaceutical company Baxter International, which is manufacturing supplies for Britain in the Czech Republic, said it could not take any more orders for H1N1 vaccines. It has already signed contracts with five countries for a total of 80 million doses.

The possibility of a territorial struggle over vaccine does not bode well for Britain ? with all of its flu vaccines produced abroad ? or the United States, which makes only 20 percent of the regular flu vaccines it uses.

Britain is in line to get around 60 million doses of the vaccine ? enough to cover half the population ? by the end of December, with the rest of the doses following next year.

The first batches are expected in August and the Government has drawn up a priority list of people to receive the jab.

However, there is expected to be some delay between when Baxter and GlaxoSmithKline, which is producing batches in Germany, deliver the supplies and people receive their first vaccinations.

Page 2 of this article

Prof Dunhill added that should governments ?nationalise? vaccine producers within their borders, then Britain would have production at Speke, near Liverpool, as its fall-back. Novartis and MedImmune, which both have multi-million dollar deals with the US Government, have bases at Speke, though it is not yet known how many doses the facilities would likely produce.

Michael Osterholm, director of the Center for Infectious Diseases Research and Policy at the University of Minnesota, said politicians would not be able to withstand the pressure.

?This isn?t rocket science. If there is severe disease, countries will want to hang onto the vaccine for their own citizens.?

David Fedson, a retired vaccine industry executive, added that the ?consequences of shipping vaccine to another country when your own people don?t have it would be devastating?.

A vaccine for Britain has to be approved by the Joint Committee on Vaccination and Immunisation (JCVI) and the Medicines and Healthcare products Regulatory Agency (MHRA) before it can be used. Sir Liam Donaldson, the Chief Medical Officer, said on Thursday that vaccine orders remained on course. ?We will get initial supplies by the end of August unless there is some problem in the manufacturing process,? he said.

In past pandemics, vaccines were never exported before the country that produced them had enough for its own population. But unlike the last two pandemics in 1957 and 1968, many more countries this time around have struck deals with companies which they say guarantee them first access to vaccine.

David Fidler, a professor of law at Indiana University who has consulted for World Health Organisation, said: ?Pandemic vaccine will be a valuable and scarce resource, like oil or food during a famine. We?ve seen how countries behave in those situations, and it?s not encouraging.?

Countries with flu vaccine plants might decide to seize all vaccines and ban their export, thus breaking the pharmaceutical contracts promising other countries vaccine supplies. These private contracts are not binding international law between two countries, Professor Fidler said.

He said most vaccine contracts include a clause allowing them to be broken under extraordinary circumstances, such as a health emergency. That would leave the countries who had brokered such deals not only without vaccine, but without legal recourse.

?There?s nothing in international law that helps you resolve this, it?s just a political nightmare happening in the midst of an epidemiological nightmare,? Prof Fidler said.

Neither the Department of Health nor the vaccine manufacturers would comment on delivery plans.
 
Re: Fight for swine flu vaccine could get ugly

The one slight advantage for the UK, is that GSK is a British company, so it is less likely to hand over vaccines or co-operate with a foreign government. However, if you're ordering from a company like Baxter which is American and based in America, you haven't got a lot of hope if the US decide to divert the vaccines.

Also GSK has a Relenza plant in the UK which currently exports most of its production.
 
Re: Fight for swine flu vaccine could get ugly

...However, if you're ordering from a company like Baxter which is American and based in America, you haven't got a lot of hope if the US decide to divert the vaccines.

The US won't benefit from Baxter for a while, at least; since the FDA hasn't yet approved their technology. All 80 million doses on order are going to other countries.

I haven't seen any anticipated date for FDA approval.

http://www.reuters.com/article/rbssHealthcareNews/idUSN1646263220090716
 
Re: Fight for swine flu vaccine could get ugly

Also GSK has a Relenza plant in the UK which currently exports most of its production.

Although Relenza is an anti-viral, not a vaccine and I think production is small in comparison to something like Tamiflu production.
 
Re: Fight for swine flu vaccine could get ugly

The US won't benefit from Baxter for a while, at least; since the FDA hasn't yet approved their technology. All 80 million doses on order are going to other countries.

I haven't seen any anticipated date for FDA approval.

http://www.reuters.com/article/rbssHealthcareNews/idUSN1646263220090716

I was aware that that it hasn't been approved by the FDA, but I used Baxter because it was the only company that I knew off the top of my head that produced vaccines in its own country (i.e. based in the US and US owned). Having said that, if it all does get a bit nasty this winter, the FDA might approve it rapidly or halt export while it seeks to approve it.
 
Re: Fight for swine flu vaccine could get ugly

Although Relenza is an anti-viral, not a vaccine and I think production is small in comparison to something like Tamiflu production.

I'm aware of both these facts but the fact that production facilities are limited worldwide actually increases the importance of the UK plant and if Tamiflu resistance becomes wide-spread in future well...

Interestingly Glaxo planned on closing their UK facility a year or so ago (with the loss of about 300 jobs) but the emergence of bird-flu saved it.
 
Re: Fight for swine flu vaccine could get ugly

Although Relenza is an anti-viral, not a vaccine and I think production is small in comparison to something like Tamiflu production.

Tamiflu production is approx 600 million doses per year at present, max.

Relenza production is approx 60 million doses per year at present, max.

That was a big issue I discussed with Dr. Fedson in the interview for the L'Osservatore Romano article, but they had to edit it out due to space constraints.
 
Back
Top